SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Evofem
Biosciences, Inc., (NASDAQ: EVFM), a clinical-stage
biopharmaceutical company, will present and host investor meetings
at the upcoming 2019 Cantor Global Healthcare Conference in
New York, NY.
The Company's presentation is scheduled for 8:55am EDT on
Friday October 4, 2019 in the Empire
Ballroom 2 of the InterContinental New York Barclay, with a
breakout to follow in Astor Suite II. The presentation will be
webcast live through the Investors section of the Evofem
Biosciences website at www.evofem.com and archived for 90-days.
About Evofem Biosciences
Evofem Biosciences, Inc., is a clinical-stage biopharmaceutical
company committed to developing and commercializing innovative
products to address unmet needs in women's sexual and reproductive
health. Evofem Biosciences aims to advance the lives of women by
developing innovative solutions, such as woman-controlled
contraception and potential protection from certain sexually
transmitted infections ("STIs"). The Company is leveraging
its proprietary Multipurpose Vaginal pH Regulator (MVP-R™) platform
to develop Amphora® (L-lactic acid, citric acid and potassium
bitartrate) for birth control and prevention of urogenital
acquisition of certain STIs. For more information, please visit
www.evofem.com.
About Amphora
Amphora is an investigational MVP-R™ designed to regulate
vaginal pH within the normal range of 3.5 to 4.5. This maintains an
acidic environment which is inhospitable to sperm as well as
certain viral and bacterial pathogens associated with sexually
transmitted infections but is integral to the survival of healthy
bacteria in the vagina. Amphora met the pre-specified primary
endpoint of AMPOWER, the Phase 3 clinical trial evaluating this
MVP-R for the prevention of pregnancy in approximately 1,400 women
at 112 centers in the United
States. In this clinical trial, Amphora had a favorable
safety profile and was well tolerated. The Company plans to
re-submit the Amphora New Drug Application (NDA) in the fourth
quarter of 2019.
The Company expects to report top-line data in the fourth
quarter of 2019 from AMPREVENCE, the double-blinded
placebo-controlled Phase 2b clinical
trial of Amphora to prevent urogenital acquisition of Chlamydia
trachomatis (primary endpoint) and Neisseria gonorrhea
(secondary endpoint) in women. This study enrolled approximately
850 women at approximately 50 centers in the United States. There are currently
no therapeutics approved for the prevention of either STI.
Amphora® is a registered trademark and MVP-R™ is a
trademark of Evofem Biosciences, Inc.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, including statements related to the
timing of the planned NDA Amphora re-submission for prevention of
pregnancy, potential FDA approval of Amphora, and the potential
commercial launch of Amphora, the anticipated results of the
Phase 2b clinical trial of Amphora to prevent urogenital
acquisition of Chlamydia
trachomatis and Neisseria gonorrhea in
women, and any expected completion date or general timing for this
clinical trial. Each of these forward-looking statements
involves risks and uncertainties. Actual results may differ
materially from those, express or implied, in these forward-looking
statements. Important factors that could impair the value of Evofem
Biosciences' assets and business are disclosed in the risk factors
contained in its Annual Report on Form 10-K filed with
the Securities and Exchange Commission and subsequent
filings. All forward-looking statements are expressly qualified in
their entirety by such factors. Evofem Biosciences does not
undertake any duty to update any forward-looking statement except
as required by law.
Investor Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
M: (917) 673-5775
Media Contact
Greg
Jawski
Porter Novelli
Greg.jawski@porternovelli.com
M: (917) 749-4964
View original content to download
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-cantor-global-healthcare-conference-on-october-4-2019-300924902.html
SOURCE Evofem Biosciences, Inc.